If you discover you’re pregnant while taking Wegovy, the standard recommendation is to stop the medication and contact your healthcare provider. The good news from early human data: first-trimester exposure to GLP-1 drugs like semaglutide has not shown a higher rate of birth defects or miscarriage compared to the general population. But the drug is not considered safe to continue during pregnancy, and there are real biological reasons for caution.
Why Wegovy Is Stopped During Pregnancy
Semaglutide, the active ingredient in Wegovy, works by mimicking a gut hormone called GLP-1 that controls appetite and blood sugar. When researchers activated this same pathway in pregnant animals, it caused fetal death, structural abnormalities, and growth problems including delayed bone development. These findings in mice, rats, and rabbits are the primary reason the drug carries a warning against use in pregnancy.
More detailed animal research has started to explain why. In one study, pregnant animals treated with semaglutide had significantly smaller fetuses, even after their blood sugar levels returned to normal. The drug appeared to shrink the part of the placenta responsible for exchanging nutrients between mother and baby. Key nutrient transporters for glucose and amino acids were reduced, and the tiny blood vessels that deliver those nutrients became fewer and smaller. In short, semaglutide seems to restrict the placenta’s ability to feed a growing fetus, and this effect appears to be independent of changes in blood sugar or other metabolic factors.
What Human Data Actually Shows
Animal studies use higher doses and longer exposures than most real-world pregnancies involve, so human data matters. A study comparing women exposed to GLP-1 drugs in the first trimester against two comparison groups (women with diabetes and women who were overweight or obese) found no increased risk of major birth defects. The rate of major birth defects in exposed women was 2.6%, which matches the background rate in the general population as tracked by European birth defect registries. The study also found no increased risk of miscarriage compared to either reference group.
This is reassuring for anyone who was taking Wegovy in the early weeks before realizing they were pregnant. Most accidental exposures happen during this window, and the available evidence suggests the risk of harm from brief early exposure is low. That said, “no signal in early data” is not the same as “proven safe,” and the studies so far have been relatively small.
How Long Semaglutide Stays in Your Body
One reason timing matters is that Wegovy lingers. Semaglutide has a half-life of about seven days, meaning it takes roughly a week for half the drug to clear your system. After your last injection, meaningful levels remain in your blood for several more weeks. This is why the manufacturer recommends stopping Wegovy at least two months before trying to conceive. That window gives the drug enough time to fully wash out before a potential pregnancy begins.
If you weren’t planning to get pregnant and discover you are while still on Wegovy, stopping immediately still limits further exposure. The drug you’ve already taken will gradually clear on its own over the following weeks.
What Changes After You Stop
Discontinuing Wegovy during pregnancy means losing its appetite-suppressing and blood sugar-regulating effects. For people who were using it primarily for weight management, the main concern is weight rebound. Pregnancy naturally involves weight gain, so the focus shifts from weight loss to healthy weight management under prenatal care.
For people who also have type 2 diabetes, the transition is more involved. The standard medications considered safer during pregnancy are insulin and metformin. Your provider will likely adjust your treatment plan to maintain blood sugar control without semaglutide.
Breastfeeding After Delivery
If you’re wondering about restarting Wegovy after the baby arrives, injectable semaglutide appears compatible with breastfeeding based on limited but encouraging data. In a study of eight nursing mothers taking subcutaneous semaglutide at doses up to 1 mg weekly, none of their milk samples contained detectable levels of the drug. Their breastfed infants, ranging from 4 to 23 months old, showed normal growth and development over the weeks they were exposed.
One important distinction: oral semaglutide tablets (sold as Rybelsus) contain an absorption-enhancing ingredient that could potentially pass into breast milk and accumulate in infants. Only the injectable forms are currently considered appropriate during breastfeeding.
Planning Ahead if You Want to Conceive
If you’re on Wegovy and thinking about getting pregnant in the near future, the clearest path is to stop the medication at least two months before you start trying. This accounts for the drug’s long half-life and provides a comfortable buffer. Many people use Wegovy to reach a healthier weight before pregnancy, which can itself improve fertility and reduce pregnancy complications. The key is building in that two-month gap between your last dose and conception.
If you’re sexually active and not using reliable contraception, an unplanned pregnancy on Wegovy is a real possibility, especially since weight loss itself can increase fertility in people who previously had irregular ovulation. Being aware of this effect and having a plan, whether that’s consistent contraception or a timeline for stopping the drug, helps avoid the anxiety of an unexpected positive test while on medication.